Abstract
Ovarian cancer (OC) is usually diagnosed at an advanced stage and is related with poor prognosis. Despite numerous studies, the pathogenesis of OC is still unknown. Recent studies indicate the role of the immune system in the development and spread of OC. The identification of factors and mechanisms involved in that process and their modulation is crucial for creating effective antitumor therapy. We investigated the potential role of Th17 cells in OC patients (n = 71) by analyzing the frequencies of Th17 cells in three different environments, i.e., peripheral blood (PB), peritoneal fluid (PF), and tissue (Th17 infiltrating cells), and the concentration of IL-17A in plasma and PF of patients in terms of their clinical and prognostic significance. Th17 cells were analyzed by flow cytometry as a percentage of CD4+ lymphocytes that expressed intracellular expression of IL-17A. The level of IL-17A in plasma and PF were determined by ELISA. Our results showed accumulation of Th17 cells among tumor-infiltrating CD4+ lymphocytes (p < 0.001 in relation to PB). Moreover, the percentage of Th17 cells in both PB and PF of OC patients was significantly lower than that in benign tumors group (n = 35). There were no significant differences in the percentage of Th17 cells in PB, PF, and tissue in relation to clinicopathological characteristics of OC patients and survival. The lower percentage of Th17 cells in the PB and PF of OC patients may promote evasion of host immune response by cancer cells. The concentration of IL-17A in plasma of OC patients was higher (p < 0.0001) than that in both benign tumors and control group (n = 10). The PF IL-17A level in OC patients was higher (p < 0.0001) than that in women with benign ovarian tumors, indicating its synthesis in OC microenvironment. Higher IL-17A level in PF is correlated with longer (median: 36.5 vs. 27 months) survival of OC patients.
Highlights
Ovarian cancer (OC) is usually diagnosed at an advanced stage of development, which translates into adverse effects of treatment
E highest percentage of CD4+ lymphocytes expressing IL-17 was detected among CD4+ T cells infiltrating ovarian cancer and it was significantly higher (p 0.001) compared to peripheral blood (PB). e percentage of CD4+IL-17+ cells was higher in the tumor than that in the peritoneal fluid; the difference did not reach statistical significance (p 0.08)
To investigate the clinical potential of CD4+IL-17+ cells, we determined its association with the patients’ clinicopathological characteristics. ere was no statistically significant difference (p > 0.05) in the percentage of CD4+IL17+ cells in PB, peritoneal fluid (PF), and tumor depending on the FIGO stage, histological grade, and type of OC according to Kurman and p = 0.001 22
Summary
Ovarian cancer (OC) is usually diagnosed at an advanced stage of development, which translates into adverse effects of treatment. E mechanisms of tumor escape from immune surveillance, tissue infiltration, and metastasis are not yet explained. The immune system produces cells with anticancer potential. The response they induce is suppressed in the tumor microenvironment (TME). Recent studies indicate the involvement of the immune system in the development and spread of ovarian cancer [1,2,3,4,5]. Abnormal vasculature is a hallmark of most solid tumors. It facilitates escape from immune surveillance and Journal of Oncology impairs perfusion and the entry of drugs from the circulation, limiting their anticancer effect [1, 5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
